Support our research.
Please consider supporting our research efforts. Your contributions have a direct impact on our work by facilitating the purchase of supplies, reagents, and research services. These resources enable us to continue groundbreaking research in understanding and treating LGL leukemia, peripheral T cell lymphomas, and acute myeloid leukemia.
If you are interested in giving opportunities supporting LGL leukemia, please contact Corley Raileanu at corley@virginia.edu or 434-243-3480 and/or visit our giving page linked below.
Recent Donations
-
Anonymous Gift Supports UVA Leukemia Research
August 2022
An anonymous donation of more than $5 million will support leukemia research and clinical trials at UVA.
Learn more about the anonymous gift.
-
LGL Leukemia Research Endowment Fund
May 2022
Brad Glass, LGL leukemia patient, and his wife, Laura Glass, create the LGL Research Endowment Fund to support LGL leukemia research at UVA.
Learn more about the LGL Leukemia Research Endowment Fund.
-
Bess Family Charitable Fund Support LGL Leukemia Research at UVA
November 2015
Entrepreneur and LGL leukemia patient, Lane Bess, supports LGL leukemia research and patient care at UVA through the Bess Family Charitable Fund.
Learn more about Lane Bess and the Bess Family contribution to LGL leukemia research at UVA.
We thank our funding sources.
Many resources are needed to support our important work and we are immensely grateful to the following grants, scholarships, foundations, and individuals that support the Loughran Lab.
Foundations and philanthropic donors:
Bess Family Charitable Fund
LGL Leukemia Foundation
Dr. Charles and Katharine Hutton Tweedy
William J. Branch
Dr. Szabolcs Szentpetery
Brad and Laura Glass
Three generous anonymous donors
The many donors from our Giving Page
Grant support:
NIH/NCI P30 CA004579
“UVA Cancer Center Support Grant”
NIH/NCI R01 CA178393
“Genomic Architecture of LGL Leukemia”
NIH/NCI P01 CA171983
“Targeting Sphingolipid Metabolism for Treatment of AML”
Project 2 “Targeting Acid Ceramidase in AML”
NIH/NIAMS R01 AR079404
“The Role of Cytotoxic T Cells in Rheumatoid Arthritis Pathogenesis”
(Principal investigator: Erika Darrah, Ph.D. (Johns Hopkins University School of Medicine))
UVA Cancer Center Fellowship
“Use of Hypomethylating Agents to Reprogram the Epigenome in Large Granular Lymphocyte Leukemia”’
UVA Cancer Center Spatial Biology Award
“Spatial Analysis of LGL Leukemia in Tissue Microenvironments”
NIH/NCI F99 CA294256
“Ceramide and Cell Metabolism: Defining the Role of Sphingolipids in Modulating Mitochondrial Bioenergetics of Chronic Lymphocytic Leukemia”
NIH/NCI F99 CA284252
“Mechanisms and In Vivo Efficacy of Synergistic Acid Ceramidase and Bcl-2 Inhibition in Acute Myeloid Leukemia”
Ivy Biomedical Innovation Fund
“Development of Novel Nano-romidepsin Based Therapeutics for the Treatment of Cancer”
Industry-sponsored research agreements
Kymera Therapeutics
“Exploring the Activity of a STAT3-Selective Targeted Protein Degrader ST3-671 in Preclinical Models of T Cell Lymphoid Malignancies”
Dren Bio, Inc.
“Efficacy of anti-CD94 monoclonal antibody (DR-01) in LGL leukemia”
Recludix Pharma
“Efficacy of Recludix small molecule STAT3 inhibitor in T-cell malignancy”
Astrazeneca
“LGL Leukemia as a Model of Cellular Immunotherapy”